Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.79 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.79 |
| ▸ | FBP1 | P09467 | 6/20 | 0.68 |
| ▸ | EGFR | P00533 | 10/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.67 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 2/20 | 0.59 |
| ▸ | KIF5B | P33176 | 2/20 | 0.59 |
| ▸ | KDR | P35968 | 2/20 | 0.59 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29711485 | 0.88 | JAK3 (1.00) | JAK3ABCB1ABCG2FBP1EGFR | |
| SCHEMBL29651 | 0.88 | JAK3 (1.00) | JAK3ABCB1ABCG2FBP1EGFR | |
| SCHEMBL29372372 | 0.88 | JAK3 (1.00) | JAK3ABCB1ABCG2FBP1EGFR | |
| SCHEMBL4477758 | 0.84 | EGFR (0.77) | JAK3FBP1EGFRERBB2ERBB4 | |
| SCHEMBL3008965 | 0.81 | FBP1 (1.00) | ABCG2FBP1EGFRERBB2ERBB4 | |
| SCHEMBL5565577 | 0.81 | FGFR1 (0.78) | FBP1EGFRERBB2ERBB4RET | |
| SCHEMBL14979614 | 0.81 | EGFR (0.71) | ABCG2FBP1EGFRERBB2ERBB4 | |
| SCHEMBL10126401 | 0.80 | JAK3 (0.65) | JAK3ABCB1ABCG2FBP1EGFR | |
| SCHEMBL13604740 | 0.78 | EGFR (0.66) | FBP1EGFRERBB2ERBB4RET | |
| SCHEMBL6665062 | 0.78 | EGFR (0.70) | JAK3ABCB1ABCG2FBP1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538231-B2 | Tyrosine kinase inhibitors | MERCK & CO, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20060276514-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2006-12-07 | — | — | US | disclosed |
| US-6326373-B1 | ASTHMA THERAPY | PARKER HUGHES INSTITUTE | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276514-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | JAK3 29/4885ABCB1 1090/4885ABCG2 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.